Ascendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says

MT Newswires Live06-15

Ascendis Pharma's (ASND) Yorvipath hypoparathyroidism therapy maintains a superior clinical profile compared with competing programs, Wedbush analysts said in a Monday note.

The company's 3.5-year data from the phase-3 PaTHway study and the 5-year data from the phase-2 PaTH Forward study of Yorvipath in hypoparathyroidism provide strong evidence for sustained clinical benefit from long-term treatment, analysts said.

Wedbush said that both studies showed high retention rates, durable efficacy, and continued improvement in renal function with longer treatment.

Quality of life improvement, which is now required by the FDA for approvals, is the strongest evidence for Yorvipath's efficacy, a key opinion leader said, according to analysts.

Wedbush has an outperform rating and a $273 price target on the stock.

Price: 223.74, Change: +5.68, Percent Change: +2.60

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643048092?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 22:54","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643048092","market":"fut","top_or_hot":-1,"title":"Ascendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says","media":"MT Newswires Live","content":"<html><body><p> Ascendis Pharma's (ASND) Yorvipath hypoparathyroidism therapy maintains a superior clinical profile compared with competing programs, Wedbush analysts said in a Monday note.</p><p>The company's 3.5-year data from the phase-3 PaTHway study and the 5-year data from the phase-2 PaTH Forward study of Yorvipath in hypoparathyroidism provide strong evidence for sustained clinical benefit from long-term treatment, analysts said.</p><p>Wedbush said that both studies showed high retention rates, durable efficacy, and continued improvement in renal function with longer treatment.</p><p>Quality of life improvement, which is now required by the FDA for approvals, is the strongest evidence for Yorvipath's efficacy, a key opinion leader said, according to analysts.</p><p>Wedbush has an outperform rating and a $273 price target on the stock.</p><p>Price: 223.74, Change: +5.68, Percent Change: +2.60</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscendis Pharma's Yorvipath Has Superior Profile Relative to Competitors, Wedbush Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-15 22:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Ascendis Pharma's (ASND) Yorvipath hypoparathyroidism therapy maintains a superior clinical profile compared with competing programs, Wedbush analysts said in a Monday note.</p><p>The company's 3.5-year data from the phase-3 PaTHway study and the 5-year data from the phase-2 PaTH Forward study of Yorvipath in hypoparathyroidism provide strong evidence for sustained clinical benefit from long-term treatment, analysts said.</p><p>Wedbush said that both studies showed high retention rates, durable efficacy, and continued improvement in renal function with longer treatment.</p><p>Quality of life improvement, which is now required by the FDA for approvals, is the strongest evidence for Yorvipath's efficacy, a key opinion leader said, according to analysts.</p><p>Wedbush has an outperform rating and a $273 price target on the stock.</p><p>Price: 223.74, Change: +5.68, Percent Change: +2.60</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643048092","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643048092","pubTimestamp":1781535244,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ascendis Pharma's  Yorvipath hypoparathyroidism therapy maintains a superior clinical profile compared with competing programs, Wedbush analysts said in a Monday note.The company's 3.5-year data from the phase-3 PaTHway study and the 5-year data from the phase-2 PaTH Forward study of Yorvipath in hypoparathyroidism provide strong evidence for sustained clinical benefit from long-term treatment, analysts said.Wedbush said that both studies showed high retention rates, durable efficacy, and continued improvement in renal function with longer treatment.Quality of life improvement, which is now required by the FDA for approvals, is the strongest evidence for Yorvipath's efficacy, a key opinion leader said, according to analysts.Wedbush has an outperform rating and a $273 price target on the stock.Price: 223.74, Change: +5.68, Percent Change: +2.60","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","SPN":"Superior Energy Services Inc","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","ASND":"Ascendis Pharma A/S"},"translate_title":"Wedbush表示，Ascendis Pharma的Yorvipath相对于竞争对手具有优越的知名度","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASND":1,"SPN":1.5},"content_text":"Ascendis Pharma's (ASND) Yorvipath hypoparathyroidism therapy maintains a superior clinical profile compared with competing programs, Wedbush analysts said in a Monday note.The company's 3.5-year data from the phase-3 PaTHway study and the 5-year data from the phase-2 PaTH Forward study of Yorvipath in hypoparathyroidism provide strong evidence for sustained clinical benefit from long-term treatment, analysts said.Wedbush said that both studies showed high retention rates, durable efficacy, and continued improvement in renal function with longer treatment.Quality of life improvement, which is now required by the FDA for approvals, is the strongest evidence for Yorvipath's efficacy, a key opinion leader said, according to analysts.Wedbush has an outperform rating and a $273 price target on the stock.Price: 223.74, Change: +5.68, Percent Change: +2.60","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643048092","isCrawlerRequest":true}